- Home
- GTE vs ZNTL Comparison
GTE vs ZNTL Comparison
Compare GTE & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GTE
- ZNTL
- Stock Information
- Founded
- GTE 2003
- ZNTL 2014
- Country
- GTE Canada
- ZNTL United States
- Employees
- GTE N/A
- ZNTL N/A
- Industry
- GTE Oil & Gas Production
- ZNTL Biotechnology: Pharmaceutical Preparations
- Sector
- GTE Energy
- ZNTL Health Care
- Exchange
- GTE Nasdaq
- ZNTL Nasdaq
- Market Cap
- GTE 253.1M
- ZNTL 238.2M
- IPO Year
- GTE N/A
- ZNTL 2020
- Fundamental
- Price
- GTE $6.28
- ZNTL $3.00
- Analyst Decision
- GTE Hold
- ZNTL Buy
- Analyst Count
- GTE 1
- ZNTL 7
- Target Price
- GTE $10.00
- ZNTL $10.86
- AVG Volume (30 Days)
- GTE 311.1K
- ZNTL 1.4M
- Earning Date
- GTE 10-29-2024
- ZNTL 11-04-2024
- Dividend Yield
- GTE N/A
- ZNTL N/A
- EPS Growth
- GTE 7.45
- ZNTL N/A
- EPS
- GTE 1.56
- ZNTL N/A
- Revenue
- GTE $658,051,000.00
- ZNTL $40,560,000.00
- Revenue This Year
- GTE $11.16
- ZNTL N/A
- Revenue Next Year
- GTE $20.54
- ZNTL N/A
- P/E Ratio
- GTE $4.04
- ZNTL N/A
- Revenue Growth
- GTE 3.94
- ZNTL N/A
- 52 Week Low
- GTE $4.72
- ZNTL $2.83
- 52 Week High
- GTE $10.40
- ZNTL $18.32
- Technical
- Relative Strength Index (RSI)
- GTE 42.99
- ZNTL 39.05
- Support Level
- GTE $6.22
- ZNTL $2.89
- Resistance Level
- GTE $6.62
- ZNTL $3.06
- Average True Range (ATR)
- GTE 0.29
- ZNTL 0.17
- MACD
- GTE 0.03
- ZNTL -0.04
- Stochastic Oscillator
- GTE 24.14
- ZNTL 12.36
About GTE Gran Tierra Energy Inc.
Gran Tierra Energy Inc is an independent energy company. It is engaged in the acquisition, exploration, development, and production of oil and gas properties. The firm produces light crude oil, supplemented with medium crude and natural gas. Gran Tierra holds interests in producing and prospective properties in Colombia and prospective properties in Ecuador. The company derives its revenue from Colombia.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as an Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. It has two lead product candidates under pipeline: ZN-c5, for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer; and ZN-c3, for the treatment of advanced solid tumors as monotherapy and ovarian cancer.